Arthur Franken

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.

SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.

Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development is focused on understanding and meeting patient needs using our novel therapies.

Calypso Biotech is a biopharmaceuticals company that discovers and develops novel therapies for auto-immune diseases.

People living with rare lung disorders are at the center of everything we do. Breath Therapeutics, a Zambon company is a private clinical-stage biopharmaceutical company specializing in advanced inhaled therapies for severe respiratory diseases with high unmet medical need. By combining novel formulations of existing drugs with cutting-edge inhalation technology to rapidly deliver high concentrations of drugs to the site of action in the lung, the company is unleashing the true potential of inhaled drug delivery. This approach increases effective dosing in the lung while minimizing systemic exposure which could lead to new treatment solutions with enhanced efficacy and safety. The Company’s pivotal late-stage program, BOSTON, is evaluating L-CsA-i, the first potential therapy for bronchiolitis obliterans syndrome (BOS), a devastating lung disease with very high mortality that commonly affects patients who have received lung or allogeneic hematopoietic stem cell transplantation. Breath Therapeutics is also evaluating a second clinical development program utilizing its drug-device innovation to address the unmet medical need in additional orphan respiratory diseases. Breath Therapeutics, a Zambon company has offices in Munich, Germany and Menlo Park, CA. For more informationPlease visit https://breath-therapeutics.com/forward-looking-disclaimer/ for forward-looking statements disclaimer.

People living with rare lung disorders are at the center of everything we do. Breath Therapeutics, a Zambon company is a private clinical-stage biopharmaceutical company specializing in advanced inhaled therapies for severe respiratory diseases with high unmet medical need. By combining novel formulations of existing drugs with cutting-edge inhalation technology to rapidly deliver high concentrations of drugs to the site of action in the lung, the company is unleashing the true potential of inhaled drug delivery. This approach increases effective dosing in the lung while minimizing systemic exposure which could lead to new treatment solutions with enhanced efficacy and safety. The Company’s pivotal late-stage program, BOSTON, is evaluating L-CsA-i, the first potential therapy for bronchiolitis obliterans syndrome (BOS), a devastating lung disease with very high mortality that commonly affects patients who have received lung or allogeneic hematopoietic stem cell transplantation. Breath Therapeutics is also evaluating a second clinical development program utilizing its drug-device innovation to address the unmet medical need in additional orphan respiratory diseases. Breath Therapeutics, a Zambon company has offices in Munich, Germany and Menlo Park, CA. For more informationPlease visit https://breath-therapeutics.com/forward-looking-disclaimer/ for forward-looking statements disclaimer.

Our Mission is to Support Timely, Efficient Patient Care, while Optimizing Laboratory and Hospital Processes & Operations. At STAT-Dx we believe in Fast Syndromic Testing to move innovative diagnostics Closer to Care. Make a difference in healthcare and join us! www.stat-dx.com

Our Mission is to Support Timely, Efficient Patient Care, while Optimizing Laboratory and Hospital Processes & Operations. At STAT-Dx we believe in Fast Syndromic Testing to move innovative diagnostics Closer to Care. Make a difference in healthcare and join us! www.stat-dx.com

Levicept Ltd is a UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. LEVI-04 is currently in a phase II study in patients with osteoarthritis of the knee.

Changing lives is what drives us at ProQR Therapeutics. We are advancing our proprietary Axiomer RNA-editing platform technology. Our highly energetic team strives to combine innovative technologies and entrepreneurism to make a meaningful impact on the lives of patients and the people around them. If you are up to this challenge and like to be part of our team, check out our website for vacancies: http://www.proqr.com/careers/

Changing lives is what drives us at ProQR Therapeutics. We are advancing our proprietary Axiomer RNA-editing platform technology. Our highly energetic team strives to combine innovative technologies and entrepreneurism to make a meaningful impact on the lives of patients and the people around them. If you are up to this challenge and like to be part of our team, check out our website for vacancies: http://www.proqr.com/careers/

Implantable Shock Absorbers for Knee OA

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.

SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.

Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development is focused on understanding and meeting patient needs using our novel therapies.

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. Gilde Healthcares lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Gilde Healthcares venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Since 2001 Gilde Healthcare has raised €2.5 billion for its specialized funds.